Psychoactive drugs

MPress Records Releases So Sure's Debut EP Caffeine Drip

Psychoactive drugs, Drugs, Neurochemistry, Caffeine, Mutagens, Stimulants, Xanthines, American Civil Liberties Union
Friday, July 10, 2020 - 9:05pm

NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.

Key Points: 
  • NEW YORK, July 10, 2020 /PRNewswire-PRWeb/ -- MPress Records recording artists So Sure have released their debut EP Caffeine Drip, with 100% of the proceeds being donated to the ACLU to aid in their advocacy efforts to demand an end to racial injustice and police brutality.
  • The full EP, available on all digital platforms and premiered by The Big Takeover , is the first offering from So Sure, which was officially formed during the Covid-19 pandemic.
  • The EP features songs that are all-too-timely and reflect the international frustration and anxiety due to the virus and recent protests sparked by the tragedy in Minneapolis.
  • So Sure's self-produced "Caffeine Drip" was recorded remotely between Savannah, GA, Montgomery, NY and Charleston, SC.

Adamas Announces New Employment Inducement Grant

Psychoactive drugs, Neurological disorders, Organ systems, Stimulants, Amantadine, Amines, Euphoriants, Parkinson's disease, L-DOPA, Dyskinesia
Friday, July 10, 2020 - 9:05pm

The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

Key Points: 
  • The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
  • At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society.
  • We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
  • In 2018, Adamas successfully launched GOCOVRI (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Canopy Rivers Portfolio Companies Look to Expand Retail and Brand Presence in North American Markets

Cannabis, Cannabis smoking, Entheogens, Euphoriants, Medicine, Psychoactive drugs, Cannabis in Canada
Friday, July 10, 2020 - 12:00pm

Dynaleo hopes that the LOI will be a first step in the company's goal to close the gap between supply and consumer demand for gummies in Canada.

Key Points: 
  • Dynaleo hopes that the LOI will be a first step in the company's goal to close the gap between supply and consumer demand for gummies in Canada.
  • Agripharm Corp. ("Agripharm") received a licence amendment from Health Canada to allow for the sale of dried cannabis, extracts, edibles, and topicals.
  • Canopy Rivers is a venture capital firm specializing in cannabis with a portfolio of 18 companies across various segments of the cannabis value chain.
  • Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

R.J. Reynolds Vapor Company Expands Modern Oral Portfolio With Dissolvable Nicotine Lozenges Under Global Brand, VELO

Smoking cessation, Psychoactive drugs, Tobacco, Electronic cigarettes, Smoking, Nicotine replacement therapy, RTT, Nicotine, Draft:Nicotine Salts
Thursday, July 9, 2020 - 7:24pm

The decision to offer VELO nicotine lozenges reflects the Company's commitment to meeting adult nicotine consumers' (ANCs) changing preferences and desire for convenience, simplicity and choice.

Key Points: 
  • The decision to offer VELO nicotine lozenges reflects the Company's commitment to meeting adult nicotine consumers' (ANCs) changing preferences and desire for convenience, simplicity and choice.
  • "We are pleased to expand the VELO product portfolio to better provide adult nicotine consumers with a range of sensorial, modern oral nicotine options," said Shay Mustafa, SVP Modern Oral, RJRVC.
  • "Bringing VELO nicotine lozenges to our portfolio reiterates our commitment to empower consumer choice and to provide adult nicotine consumers with products that fit modern lifestyles."
  • About R.J. Reynolds Vapor Company and Reynolds American Inc.
    R.J. Reynolds Vapor Company ("RJRVC") is an operating company of Reynolds American Inc. ("RAI"), a member of the British American Tobacco Group.

ATAI Life Sciences takes on opioid crisis by acquiring Kures to develop novel therapeutics for opioid abuse

Psychoactive drugs, Euphoriants, Analgesics, Opioids, Organic compounds, RTT, Ethers, Indole alkaloids, Mitragynine
Thursday, July 9, 2020 - 5:30pm

Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.

Key Points: 
  • Additionally, Srinivas Rao, MD, PhD, Chief Scientific Officer of ATAI Life Sciences, has been appointed CEO of Kures.
  • Both mitragynine and KUR-101 are atypical opioid receptor modulators, boasting unique pharmacology that may make them safer than currently available opioids in treating pain.
  • Moreover, it is estimated that 8-12% of individuals prescribed opioids for chronic pain ultimately develop opioid use disorder.
  • "Kures is excited to have the resources and commitment of ATAI in advancing our promising therapeutic compounds," added Andrew Kruegel, CSO and co-founder of Kures.

Flor Americas Opens Seed Funding Round for Expansion in Global Cannabinoid Export Market

Alternative medicine, Health, Manufacturing, Agriculture, Natural Resources, Other Manufacturing, Pharmaceutical, Entheogens, Euphoriants, Cannabis, Cannabis smoking, Hemp, Legality of cannabis, Psychoactive drugs, Plants, Drugs
Thursday, July 9, 2020 - 2:02pm

Flor Americas, a vertically integrated manufacturer of pharmaceutical-grade cannabinoids for global markets, today announced the opening of its seed funding round to expand company infrastructure and operations.

Key Points: 
  • Flor Americas, a vertically integrated manufacturer of pharmaceutical-grade cannabinoids for global markets, today announced the opening of its seed funding round to expand company infrastructure and operations.
  • With our company headquarters and manufacturing facility located within Uruguays free-trade zone, Flor Americas is building its network as a leading South American export partner, said Roy McFarland, CEO.
  • Coupled with its wholly owned subsidiary cultivation operation on 1,500 hectares (5.8 square miles), Flor Americas is well-positioned to scale its production to meet global market demand, which grew 91% last year outside the U.S. and Canada.
  • Flor Americas brings together sustainable cultivation methodologies and science-based manufacturing to advance the global cannabis supply chain.

Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories

Psychoactive drugs, Morphine, Drugs, Health, RTT, Euphoriants, Morphinans, KannaLife, Patent, Pharmaceutical industry, Opioid, Heroin
Thursday, July 9, 2020 - 2:00pm

Between our PCT patents, KLS-13019 and our other novel therapeutic agents like Atopidine we have near-global coverage in the worlds top pharmaceutical markets.

Key Points: 
  • Between our PCT patents, KLS-13019 and our other novel therapeutic agents like Atopidine we have near-global coverage in the worlds top pharmaceutical markets.
  • Current off-label prescription of opioids, a leading agitator of overdose deaths and addiction, is the model of treatment.
  • Of the 19 patents issued to Kannalife, two are U.S. patents, and 17 are foreign patents.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Global Alcoholic Drinks Market 2020-2024 | Evolving Opportunities with Anheuser Busch InBev SA/NV and Bacardi Global Brands Ltd. | Technavio

Retail, Food, Beverage, Wine & Spirits, Psychoactive drugs, Alcoholic drinks, Drinking culture, Anxiolytics, Drug culture, Drink
Thursday, July 9, 2020 - 1:15pm

The global alcoholic drinks market is expected to grow by 18.88 bn liters as per Technavio.

Key Points: 
  • The global alcoholic drinks market is expected to grow by 18.88 bn liters as per Technavio.
  • In addition, the demand for lighter alcoholic beverages that pose fewer health risks is anticipated to boost the growth of the alcoholic drinks market.
  • In addition, the demand for premium alcoholic drinks has been growing faster in comparison to regular priced alcoholic drinks.
  • Therefore, the increasing focus on product premiumization is one of the key factors driving the growth of the global alcoholic drinks market.

Generation Hemp and Halcyon Thruput Enter Into Joint Toll Processing Agreement With GenCanna

Agriculture, Alternative medicine, Natural Resources, Health, Pharmaceutical, Drugs, Organ systems, Biofuels, Hemp, Herbs, Cannabidiol, Halcyon, Psychoactive drugs, Cannabis
Thursday, July 9, 2020 - 1:30pm

Dallas-based Hemp companies Generation Hemp, Inc. (OTCPK: GENH) and its affiliate, Halcyon Thruput, LLC (Halcyon), announced today the execution of a new Toll Processing Agreement with GenCanna Acquisition Corp. (GenCanna), a leading Kentucky-based hemp processor and CBD product manufacturer.

Key Points: 
  • Dallas-based Hemp companies Generation Hemp, Inc. (OTCPK: GENH) and its affiliate, Halcyon Thruput, LLC (Halcyon), announced today the execution of a new Toll Processing Agreement with GenCanna Acquisition Corp. (GenCanna), a leading Kentucky-based hemp processor and CBD product manufacturer.
  • Under the terms of the agreement, Halcyon will dry, process, and store significant amounts of hemp biomass assets for GenCanna that will be used in cannabidiol (CBD) extraction.
  • In conjunction with this new Toll Processing Agreement, Halcyon has upgraded its Kentucky based facility with four new belt dryers.
  • Andrew Barnett, GenCannas Chief Executive Officer, added, We are excited to establish this new business relationship with Generation Hemp and Halcyon Thruput.

Non-Alcoholic Beverage Market in India, Forecast to 2025 - Marketing Activities by Leading Brands, Including Endorsements by Leading Film Stars, Driving Growth

Food and drink, Psychoactive drugs, Articles, Drinks, Convenience foods, Soft drinks, The Coca-Cola Company, Alcoholic drink, Cola, Functional beverage, Container-deposit legislation
Thursday, July 9, 2020 - 12:30pm

Growth of non-alcoholic beverage market in India can be attributed to rising awareness about healthy lifestyle & wellness, rising disposable income and an increasing number of people consuming soft drinks and juices with their meals.

Key Points: 
  • Growth of non-alcoholic beverage market in India can be attributed to rising awareness about healthy lifestyle & wellness, rising disposable income and an increasing number of people consuming soft drinks and juices with their meals.
  • Moreover, marketing activities by leading brands, including endorsements by leading film stars, have also been driving non-alcoholic beverage consumption in India.
  • North India dominated the country's non-alcoholic beverage market in 2019, and the region is expected to maintain its dominance during the forecast period.
  • Some of the major players operating in India Non-Alcoholic Beverage market are Hindustan Coca Cola Beverages Pvt.